These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26470799)

  • 21. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction].
    Kaputovskij AA
    Urologiia; 2019 Dec; (6):146-149. PubMed ID: 32003186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
    Wang Y; Bao Y; Liu J; Duan L; Cui Y
    Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Yuan RQ
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily dosing of PDE5 inhibitors: where does it fit in?
    Lee KC; Brock GB
    Curr Urol Rep; 2013 Aug; 14(4):269-78. PubMed ID: 23775467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.
    Calogero AE; Burgio G; Condorelli RA; Cannarella R; La Vignera S
    Aging Male; 2018 Dec; 21(4):272-280. PubMed ID: 29378485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update].
    He PB; Zha PJ; Xu DP
    Zhonghua Nan Ke Xue; 2014 Jul; 20(7):651-6. PubMed ID: 25095624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Giuliano F; Rouprêt M; Doridot G; de la Taille A
    Prog Urol; 2013 Apr; 23(5):283-95. PubMed ID: 23545003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
    Cantrell MA; Baye J; Vouri SM
    Pharmacotherapy; 2013 Jun; 33(6):639-49. PubMed ID: 23529917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED.
    Sebastianelli A; Spatafora P; Morselli S; Vignozzi L; Serni S; McVary KT; Kaplan S; Gravas S; Chapple C; Gacci M
    Curr Urol Rep; 2020 Oct; 21(12):56. PubMed ID: 33108544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Safety of tadalafil in patients with cardiovascular comorbidities].
    Nikitina IL; Gaysina GG; Galimov SN; Bulygin KV; Galimova EF; Pavlov VN
    Urologiia; 2019 Apr; (1):119-124. PubMed ID: 31184029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
    Sun Y; Peng B; Lei GL; Wei Q; Yang L
    Minerva Urol Nefrol; 2020 Feb; 72(1):13-21. PubMed ID: 31241273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.